Asio Capital LLC Has $4.37 Million Position in Eli Lilly and Company (NYSE:LLY)

Asio Capital LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,292 shares of the company’s stock after acquiring an additional 35 shares during the quarter. Asio Capital LLC’s holdings in Eli Lilly and Company were worth $4,371,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. FPC Investment Advisory Inc. boosted its stake in Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock valued at $45,000 after purchasing an additional 43 shares during the period. Mascagni Wealth Management Inc. bought a new stake in Eli Lilly and Company in the 4th quarter valued at $43,000. Prudent Man Investment Management Inc. bought a new stake in Eli Lilly and Company in the 4th quarter valued at $48,000. Capital A Wealth Management LLC bought a new stake in Eli Lilly and Company in the 4th quarter valued at $63,000. Finally, Bellwether Advisors LLC bought a new stake in Eli Lilly and Company in the 4th quarter valued at $66,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $818.56 on Friday. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The stock has a fifty day moving average price of $775.43 and a 200-day moving average price of $801.59. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The firm has a market cap of $775.78 billion, a PE ratio of 69.90, a P/E/G ratio of 1.40 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same period in the previous year, the company earned $2.58 earnings per share. Eli Lilly and Company’s revenue was up 45.2% on a year-over-year basis. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 48.82%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on LLY. Hsbc Global Res downgraded Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. HSBC downgraded Eli Lilly and Company from a “buy” rating to a “reduce” rating and cut their target price for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Morgan Stanley reiterated an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Wall Street Zen upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Saturday, June 7th. Finally, The Goldman Sachs Group upgraded Eli Lilly and Company from a “neutral” rating to a “buy” rating and cut their target price for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.